Skip to Main Content
Use tab to navigate through the menu items.
Nasal Vaccine, New Solution For Global Health
Shionogi and HanaVax Enter into a License Agreement for COVID-19 Vaccine Development
"MucoRice" a rice-based oral vaccine was introduced in RUPTLY.
Published a paper on rice-based oral vaccine "MucoRice" by our founder.
Edible Cholera vaccine made of powdered rice proves safe in phase 1 human trials Study points towards role of gut microbiome in vaccine...
Dr. Nakahashi, a scientific advisor, has published a paper on nasal vaccines.
A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci Rika Nakahashi-Ouchida,Yohei...
A paper on cationized nanogel PspA nasal vaccine was published in "Molecular Pharmaceutical".
Characterization and Specification of a Trivalent Protein-Based Pneumococcal Vaccine Formulation Using an Adjuvant-Free Nanogel Nasal...
Sep 30, 2020
SHIONOGI and HanaVax Enter into License Agreement for Streptcoccus Pneumoniae Vaccine Candidate